AstraZeneca today announced that the United States District Court for the District of New Jersey ruled that AstraZeneca's US Patent No. 6,598,603 ("the '603 patent"), protecting PULMICORT RESPULES in ...

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/5rp48m/investigation) has announced the addition of the "Investigation ...

Sept. 28, 2005 ( updated Oct. 6, 2005) -- The U.S. Food and Drug Administration (FDA) approved safety labeling revisions in June to advise that doxercalciferol dose reductions are recommended in ...

AstraZeneca today announced that the US District Court for the District of New Jersey ruled US Patent No. 7,524,834 ("the '834 patent"), protecting PULMICORT RESPULES in the US, is invalid.

Teva announced the launch of Budesonide Inhalation Suspension, the generic version of AstraZeneca‘s Pulmicort Respules. Pulmicort Respules are indicated as maintenance treatment to control and prevent ...

A week is not normally a long time in patent disputes but it has been long enough for AstraZeneca and Teva to settle their difference over a generic version of the former’s asthma drug Pulmicort. A ...

Budesonide (Budecort Respules) is a corticosteroid, prescribed for inflammatory bowel disease, asthma, and also for breathing trouble. Budesonide is indicated for: 1. Treatment of Mild to Moderate ...

On 19 November 2008, AstraZeneca was granted a Temporary Restraining Order (TRO) by the United States District Court for the District of New Jersey, halting sales of Teva's budesonide inhalation ...

AstraZeneca has filed a lawsuit in New Jersey, USA in a bid to stop Canadian drugmaker Apotex from marketing its generic version of the asthma drug Pulmicort Respules. AstraZeneca has filed a lawsuit ...

COURT GRANTS ASTRAZENECA PRELIMINARY INJUNCTION AGAINST APOTEX IN PULMICORT RESPULES PATENT LITIGATION On 20 May 2009, the US District Court for the District of New Jersey granted AstraZeneca's ...

San Diego, Calif. – May 24, 2005 – Young children who are adherent with asthma controller therapies overall, and specifically PULMICORT RESPULES® (budesonide inhalation suspension), have lower ...